Premium
Cerebrospinal fluid NCAM levels are modulated by disease‐modifying therapies
Author(s) -
Axelsson Markus,
Dubuisson Nicolas,
Novakova Lenka,
Malmeström Clas,
Giovani Gavin,
Lycke Jan,
Gnanapavan Sharmilee
Publication year - 2019
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.13069
Subject(s) - natalizumab , multiple sclerosis , mitoxantrone , medicine , cerebrospinal fluid , fingolimod , gastroenterology , biomarker , immunology , chemotherapy , chemistry , biochemistry
Background Little is known about what leads to recovery between relapses in multiple sclerosis (MS), particularly following treatment. In the past, it has been demonstrated that soluble neural cell adhesion molecule (sNCAM), a putative biomarker of neuroplasticity, increased following steroid treatment in the Cerebrospinal fluid (CSF) of MS subjects undergoing acute relapses. Taking this a step further, we have evaluated the effect of disease‐modifying treatment (DMTs) on CSF sNCAM levels in various subtypes of MS. Methods We measured CSF sNCAM levels at baseline and after 12‐24 months of DMT in 69 patients, 49 relapsing‐remitting MS (RRMS), 20 progressive MS(PMS), and 24 healthy controls (HC) using an in‐house ELISA. Of this, 31 patients had received natalizumab, 17 mitoxantrone, and 21 fingolimod. Changes in disability were measured using EDSS and disease severity by MSSS. In conjunction, CSF NfL levels were also measured. Results At baseline, the mean sNCAM level was 268.7 ng/mL (SD: 109 ng/mL) in MS patients compared with 340.6 ng/ml (SD: 139 ng/mL) in HC, and PMS had significantly lower sNCAM (239.2 ng/mL, SD: 123.0, P = 0.019) compared to RRMS (269.4, SD: 127.4, P = 0.043). After natalizumab and mitoxantrone treatments, we observed an increase in mean sNCAM. However, in the fingolimod‐treated group, mean sNCAM decreased. There was no correlation found with EDSS or MSSS, or NfL levels as a whole. Conclusions Cerebrospinal fluid sNCAM levels were found to be lower in MS than in HC and the lowest sNCAM levels were found in PMS. Following natalizumab and mitoxantrone treatments, we observed an elevation in sNCAM levels, an effect that was not observed following fingolimod treatment. These changes, however, did not appear to correlate with disability in the short‐term or NfL levels.